BioNTech nabs PhI antibody and a new US base out of bankruptcy; Pfizer wins conditional drug OK

? BioNTech is buying MabVax?s labs $MBVX and a clinical asset out of bankruptcy as the German mRNA company establishes a satellite operation in San Diego. The biotech, which has evidently been kicking around a monster IPO, acquired the bankrupt operation?s lead candidate, MVT-5873, ?as well as other pre-clinical antibody assets to expand and complement its existing antibody portfolio.? That lead Phase I program is described as an IgG1 monoclonal antibody targeting sialyl Lewis A (SLeA), ?an epitope expressed in pancreatic and other GI cancers that plays a role in tumor adhesion and metastasis formation.? No terms were given, but BioNTech made clear in its statement that they plan to use the new base to help with